JNJ-40411813

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
01220142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as… (More)
  • figure 1
  • table 1
Is this relevant?
2017
2017
OBJECTIVE The metabotropic glutamate receptor subtype 2 (mGlu2 ) possesses both orthosteric and allosteric modulatory sites, are… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2016
2016
Alterations in rapid eye movement sleep (REM) have been suggested as valid translational efficacy markers: activation of the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
This phase 2a, randomized, multicenter, double-blind, proof-of-concept study was designed to evaluate, efficacy, safety and… (More)
Is this relevant?
2015
2015
Compounds modulating metabotropic glutamate type 2 (mGlu2) receptor activity may have therapeutic benefits in treating… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
JNJ-40411813/ADX71149 (1-butyl-3-chloro-4-(4-phenylpiperidin-1-yl) pyridin-2(1H)-one) is a positive allosteric modulator (PAM) of… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2015
2015
Metabotropic glutamate receptor-2 positive allosteric modulator, JNJ-40411813 (ADX71149), was characterised for clinical effects… (More)
  • figure 1
  • table 1
  • figure 2
  • table 3
  • table 4
Is this relevant?
2014
2014
We previously reported the discovery of 4-aryl-substituted pyridones with mGlu2 PAM activity starting from the HTS hit 5. In this… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?